Tema Cardiovascular and Metabolics ETF Rating $28.60 -0.60 (-2.05%) As of 05/1/2025 03:15 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.79Holdings in HRTS have an aggregate rating of Moderate Buy based on 639 analyst ratings issued in the past year covering 38 companies (83.8% of the portfolio).HRTS Aggregate Price Target$28.60High Prediction$28.60Average Prediction$28.60Low Prediction$28.60Holdings in HRTS have an aggregate price target of $28.60 and a range of $28.60 to $28.60 covering 38 companies (83.8% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 38 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.03%LLYEli Lilly and Company$794.67-11.6%4.9837 of 5 stars2.80$1,000.32 25.9%20Earnings ReportAnalyst ForecastHigh Trading Volume4.83%UNHUnitedHealth Group$400.07-2.8%4.9383 of 5 stars3.00$596.86 49.2%24Analyst ForecastOptions VolumeHigh Trading Volume4.09%ABTAbbott Laboratories$130.96+0.2%4.8951 of 5 stars2.84$142.59 8.9%19Positive News3.86%RHHBYRoche$39.58-2.9%N/A2.388Short Interest ↑3.54%VRTXVertex Pharmaceuticals$498.86-2.1%3.9345 of 5 stars2.64$514.91 3.2%25Upcoming EarningsPositive News3.16%BSXBoston Scientific$103.16+0.3%4.5236 of 5 stars3.04$114.52 11.0%23Analyst UpgradePositive News2.96%BBIOBridgeBio Pharma$38.40+0.1%4.5498 of 5 stars2.92$57.09 48.7%12Earnings ReportAnalyst ForecastNews CoverageHigh Trading Volume2.94%GILDGilead Sciences$103.25-3.1%4.7136 of 5 stars2.78$110.55 7.1%27Dividend Announcement2.92%CRNXCrinetics Pharmaceuticals$33.52+0.4%3.6538 of 5 stars2.92$73.00 117.8%13Upcoming EarningsNews CoveragePositive News2.91%MDTMedtronic$83.43-1.6%4.5384 of 5 stars2.44$96.14 15.2%16Positive News2.67%TMOThermo Fisher Scientific$419.88-2.1%4.8533 of 5 stars2.81$607.43 44.7%21Analyst ForecastInsider TradeShort Interest ↑2.58%MRKMerck & Co., Inc.$83.30-2.2%5 of 5 stars2.59$111.13 33.4%22Insider TradeAnalyst Revision2.28%ABBVAbbVie$193.40-0.9%4.6186 of 5 stars2.89$211.41 9.3%27Earnings ReportAnalyst ForecastAnalyst Revision2.27%CYTKCytokinetics$42.92+0.2%4.1741 of 5 stars2.94$79.13 84.4%18Upcoming EarningsInsider Trade2.13%BMYBristol-Myers Squibb$49.53-1.3%4.632 of 5 stars2.32$58.00 17.1%22Insider TradeAnalyst Revision2.13%EWEdwards Lifesciences$75.31-0.2%4.61 of 5 stars2.42$79.45 5.5%24Short Interest ↓2.00%DHRDanaher$196.90-1.2%4.9071 of 5 stars2.80$264.40 34.3%20Insider TradeShort Interest ↑1.89%MCKMcKesson$706.54-0.9%4.4739 of 5 stars2.88$681.00 -3.6%16Upcoming EarningsDividend AnnouncementAnalyst ForecastPositive News1.85%REGNRegeneron Pharmaceuticals$590.00-1.5%4.8269 of 5 stars2.88$892.60 51.3%26Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision1.75%PODDInsulet$250.25-0.8%4.4867 of 5 stars2.76$293.94 17.5%17Upcoming EarningsAnalyst Downgrade1.74%AMGNAmgen$283.78-2.5%4.0749 of 5 stars2.43$310.57 9.4%23Earnings ReportPositive News1.72%ASNDAscendis Pharma A/S$167.47-1.7%2.3058 of 5 stars2.93$204.67 22.2%15News CoveragePositive News1.66%MREOMereo BioPharma Group$2.60+0.4%2.3316 of 5 stars3.25$7.71 196.7%81.66%ALNYAlnylam Pharmaceuticals$255.13-3.1%4.2195 of 5 stars2.77$315.58 23.7%26Earnings ReportAnalyst DowngradePositive News1.57%DXCMDexCom$70.26-1.6%4.9163 of 5 stars2.95$99.00 40.9%20Earnings ReportPositive News1.37%INSMInsmed$72.64+0.9%4.3536 of 5 stars3.00$94.00 29.4%16Upcoming EarningsPositive News1.31%MDGLMadrigal Pharmaceuticals$327.70-1.9%3.7438 of 5 stars3.00$409.00 24.8%9Earnings ReportUpcoming EarningsNews CoveragePositive NewsHigh Trading Volume1.25%MASIMasimo$163.65+1.7%3.7931 of 5 stars2.83$194.80 19.0%6Upcoming EarningsPositive News1.15%IONSIonis Pharmaceuticals$31.71+3.3%4.2663 of 5 stars2.65$56.67 78.7%20Earnings ReportAnalyst ForecastNews CoveragePositive News1.15%GPCRStructure Therapeutics$27.33+1.2%2.2096 of 5 stars3.00$81.29 197.4%8Upcoming EarningsNews Coverage1.07%VKTXViking Therapeutics$28.61-0.9%4.4943 of 5 stars3.00$87.15 204.6%14Analyst UpgradeOptions VolumeAnalyst Revision0.93%ARWRArrowhead Pharmaceuticals$14.04+1.1%3.6117 of 5 stars2.60$41.44 195.2%10Positive News0.86%AKROAkero Therapeutics$45.31-0.7%3.7933 of 5 stars3.00$76.29 68.4%9Upcoming EarningsPositive News0.82%MIRMMirum Pharmaceuticals$43.42-0.1%4.2422 of 5 stars3.09$58.20 34.0%11Upcoming EarningsPositive News0.82%WSTWest Pharmaceutical Services$210.45-0.4%4.6419 of 5 stars3.00$332.50 58.0%80.45%RCKTRocket Pharmaceuticals$7.86+3.0%4.6753 of 5 stars2.92$43.00 447.1%12Upcoming EarningsHigh Trading Volume0.26%NTLAIntellia Therapeutics$8.64-2.6%4.6688 of 5 stars2.65$36.68 324.6%20Upcoming Earnings0.25%MTSRMetsera$23.36-3.1%N/A3.00$47.00 101.2%4 This page (NASDAQ:HRTS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTS Stock Free HRTS Stock Alerts